CCCC C4 Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662579 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.2%
TTM net income YoY23.5%
TTM EPS YoY62.3%
Revenue 3-yr CAGR16.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-315.9%
Net margin-282.2%
FCF margin-247.1%
EBITDA margin-311.2%
Returns
ROE-47.6%
ROA-30.5%
ROIC (approx.)-55.3%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets31.2%
Debt / equity0.00x
Current ratio5.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.47M | $6.64M | $6.15M | $11.02M | $11.23M | $6.46M | $7.24M | $5.18M |
| R&D expense | $24.80M | $24.47M | $24.61M | $24.98M | $25.99M | $26.20M | $27.07M | $32.51M |
| SG&A expense | $8.26M | $8.59M | $9.33M | $9.18M | $8.92M | $8.77M | $9.33M | $10.37M |
| Operating income | -$24.60M | -$26.42M | -$27.79M | -$23.14M | -$34.41M | -$28.50M | -$29.16M | -$37.71M |
| Pretax income | — | — | — | -$20.36M | -$32.17M | -$26.02M | -$26.32M | -$34.44M |
| Income tax | $0 | $0 | $0 | $121,000 | $0 | $0 | $0 | $131,000 |
| Net income | -$21.84M | -$23.64M | -$25.13M | -$20.49M | -$32.17M | -$26.02M | -$26.32M | -$34.57M |
| EBITDA | -$24.28M | -$26.09M | -$27.38M | -$22.72M | -$34.03M | -$28.09M | -$28.71M | -$37.23M |
| EPS (basic) | -0.16 | -0.18 | -0.20 | — | -0.44 | -0.37 | -0.37 | — |
| EPS (diluted) | -0.16 | -0.18 | -0.20 | — | -0.44 | -0.37 | -0.37 | — |
| Weighted avg. shares (diluted) | 136.08M | 130.70M | 126.07M | — | 72.56M | 71.01M | 70.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $32.42M | $78.61M | $61.27M | $74.60M | $58.81M | $78.16M | $51.29M | $58.94M |
| Receivables | $1.41M | $1.33M | $2.88M | $2.40M | $6.54M | $2.16M | $8.03M | $3.10M |
| Current assets | $214.50M | $262.90M | $245.37M | $258.11M | $206.86M | $224.73M | $232.53M | $257.77M |
| PP&E, net | $3.83M | $4.15M | $4.49M | $4.74M | $5.13M | $5.54M | $5.48M | $5.84M |
| Total assets | $331.80M | $359.40M | $328.86M | $359.07M | $265.49M | $296.53M | $319.52M | $349.60M |
| Current liabilities | $41.46M | $48.25M | $27.25M | $33.03M | $35.95M | $44.46M | $40.82M | $45.18M |
| Total liabilities | $103.63M | $112.14M | $94.61M | $102.49M | $111.08M | $122.46M | $124.38M | $133.62M |
| Shareholders' equity | $228.17M | $247.26M | $234.25M | $256.59M | $154.41M | $174.06M | $195.14M | $215.99M |
| Shares outstanding | 131.31M | 122.91M | 104.04M | 96.91M | 74.17M | 71.01M | 70.99M | 70.63M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.97M | -$1.57M | -$29.94M | -$22.14M | -$31.21M | -$12.06M | -$33.28M | -$17.93M |
| Capital expenditure | $0 | $37,000 | $64,000 | $11,000 | $411,000 | $185,000 | $0 | -$4,000 |
| Free cash flow | -$25.97M | -$1.61M | -$30.01M | -$22.16M | -$31.62M | -$12.24M | -$33.28M | -$17.93M |
| Investing cash flow | -$20.58M | -$14.81M | $16.15M | -$80.73M | $4.09M | $38.92M | $29.12M | $13.67M |
| Financing cash flow | $359,000 | $33.73M | $462,000 | $118.67M | $7.77M | $0 | -$46,000 | $112,000 |
| Depreciation & amortization | $320,000 | $336,000 | $404,000 | $428,000 | $384,000 | $416,000 | $456,000 | $480,000 |
| Stock-based compensation | $2.98M | $3.04M | $2.67M | $4.01M | $4.59M | $4.99M | $5.51M | $8.23M |
| Share buybacks | $39,000 | $0 | $200,000 | $14,000 | $24,000 | $0 | $155,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.